Research programme: plasma kallikrein inhibitors - KalVista Pharmaceuticals
Latest Information Update: 29 Nov 2016
At a glance
- Originator Vantia Therapeutics
- Developer KalVista Pharmaceuticals
- Class Small molecules
- Mechanism of Action Plasma-kallikrein-inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Diabetic macular oedema; Hereditary angioedema